Namir Hassan becomes CSO at Zelluna Immunotherapy

Company
Zelluna Immunotherapy AS
Appointee name
Namir Hassan
Country

Norway

Namir Hassan, a T cell biologist, has joined Zelluna Immunotherapy AS as chief scientific officer to help oversee development of the company’s portfolio of T cell receptors (TCR) derived from cancer patients. He was most recently a vice president at Immunocore Ltd where he managed the company’s biology, preclinical and biomarker units targeting cancer.  In this role, he oversaw the first-in-human trial of a TCR-based biologic targeting a melanoma antigen. Dr Hassan also worked in discovery research at GlaxoSmithKline Plc and at the Ludwig Institute for Cancer Research. He received a Doctor of Philosophy from the University of Oxford in T cell biology.

Zelluna Immunotherapy announced the appointment on 13 August 2018.

Copyright 2018 Evernow Publishing Ltd.